- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00764790
Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine Versus a Licensed Comparator in Children
Immunogenicity and Safety of GSK Biologicals' Thimerosal-free TIV Flu Vaccine Versus a Licensed Comparator in Children
Studieoversikt
Studietype
Registrering (Faktiske)
Fase
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35244
- GSK Investigational Site
-
Birmingham, Alabama, Forente stater, 35205
- GSK Investigational Site
-
Dothan, Alabama, Forente stater, 36305
- GSK Investigational Site
-
-
Arkansas
-
Benton, Arkansas, Forente stater, 72019
- GSK Investigational Site
-
Conway, Arkansas, Forente stater, 72034
- GSK Investigational Site
-
Fayetteville, Arkansas, Forente stater, 72703
- GSK Investigational Site
-
Jonesboro, Arkansas, Forente stater, 72401
- GSK Investigational Site
-
Little Rock, Arkansas, Forente stater, 72205
- GSK Investigational Site
-
-
California
-
Huntington Beach, California, Forente stater, 92647
- GSK Investigational Site
-
Long Beach, California, Forente stater, 90806
- GSK Investigational Site
-
Paramount, California, Forente stater, 90723
- GSK Investigational Site
-
Sacramento, California, Forente stater, 95816
- GSK Investigational Site
-
San Francisco, California, Forente stater, 94102
- GSK Investigational Site
-
West Covina, California, Forente stater, 91790
- GSK Investigational Site
-
-
Colorado
-
Longmont, Colorado, Forente stater, 80501
- GSK Investigational Site
-
-
Connecticut
-
Norwich, Connecticut, Forente stater, 06360
- GSK Investigational Site
-
-
Idaho
-
Nampa, Idaho, Forente stater, 83686
- GSK Investigational Site
-
-
Illinois
-
DeKalb, Illinois, Forente stater, 60115
- GSK Investigational Site
-
-
Indiana
-
New Albany, Indiana, Forente stater, 47150
- GSK Investigational Site
-
-
Kansas
-
Arkansas City, Kansas, Forente stater, 67005
- GSK Investigational Site
-
Newton, Kansas, Forente stater, 67114
- GSK Investigational Site
-
Wichita, Kansas, Forente stater, 67207
- GSK Investigational Site
-
-
Kentucky
-
Bardstown, Kentucky, Forente stater, 40004
- GSK Investigational Site
-
Louisville, Kentucky, Forente stater, 40207
- GSK Investigational Site
-
-
Louisiana
-
Bossier City, Louisiana, Forente stater, 71111
- GSK Investigational Site
-
Metairie, Louisiana, Forente stater, 70006
- GSK Investigational Site
-
-
Michigan
-
Stevensville, Michigan, Forente stater, 49127
- GSK Investigational Site
-
-
Minnesota
-
Saint Paul, Minnesota, Forente stater, 55108
- GSK Investigational Site
-
-
Missouri
-
Saint Louis, Missouri, Forente stater, 63141
- GSK Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68134
- GSK Investigational Site
-
-
Nevada
-
Henderson, Nevada, Forente stater, 89015
- GSK Investigational Site
-
-
New York
-
Cortland, New York, Forente stater, 13045
- GSK Investigational Site
-
-
North Carolina
-
Boone, North Carolina, Forente stater, 28607
- GSK Investigational Site
-
Cary, North Carolina, Forente stater, 27518
- GSK Investigational Site
-
Raleigh, North Carolina, Forente stater, 27609
- GSK Investigational Site
-
-
North Dakota
-
Fargo, North Dakota, Forente stater, 58103
- GSK Investigational Site
-
-
Ohio
-
Austintown, Ohio, Forente stater, 44515
- GSK Investigational Site
-
Cincinnati, Ohio, Forente stater, 45245
- GSK Investigational Site
-
Cleveland, Ohio, Forente stater, 44121
- GSK Investigational Site
-
Dayton, Ohio, Forente stater, 45406
- GSK Investigational Site
-
-
Oregon
-
Gresham, Oregon, Forente stater, 97030
- GSK Investigational Site
-
-
Pennsylvania
-
Erie, Pennsylvania, Forente stater, 16505
- GSK Investigational Site
-
Greenville, Pennsylvania, Forente stater, 16125
- GSK Investigational Site
-
Latrobe, Pennsylvania, Forente stater, 15650
- GSK Investigational Site
-
Pittsburgh, Pennsylvania, Forente stater, 15236
- GSK Investigational Site
-
Uniontown, Pennsylvania, Forente stater, 15401
- GSK Investigational Site
-
Wexford, Pennsylvania, Forente stater, 15090
- GSK Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, Forente stater, 29406
- GSK Investigational Site
-
-
Tennessee
-
Clarksville, Tennessee, Forente stater, 37043
- GSK Investigational Site
-
Jackson, Tennessee, Forente stater, 38305
- GSK Investigational Site
-
Kingsport, Tennessee, Forente stater, 37660
- GSK Investigational Site
-
-
Texas
-
Austin, Texas, Forente stater, 78705
- GSK Investigational Site
-
Fort Worth, Texas, Forente stater, 76135
- GSK Investigational Site
-
Houston, Texas, Forente stater, 77055
- GSK Investigational Site
-
San Angelo, Texas, Forente stater, 76904
- GSK Investigational Site
-
-
Utah
-
Bountiful, Utah, Forente stater, 84010
- GSK Investigational Site
-
Layton, Utah, Forente stater, 84041
- GSK Investigational Site
-
Murray, Utah, Forente stater, 84107
- GSK Investigational Site
-
Provo, Utah, Forente stater, 84604
- GSK Investigational Site
-
Roy, Utah, Forente stater, 84067
- GSK Investigational Site
-
South Jordan, Utah, Forente stater, 84095
- GSK Investigational Site
-
-
Virginia
-
Burke, Virginia, Forente stater, 22015
- GSK Investigational Site
-
-
-
-
-
Pokfulam, Hong Kong
- GSK Investigational Site
-
Shatin, Hong Kong
- GSK Investigational Site
-
-
-
-
-
Mexico, Mexico, 6720
- GSK Investigational Site
-
Mexico city, Mexico, 04530
- GSK Investigational Site
-
-
-
-
-
Taipei, Taiwan, 104
- GSK Investigational Site
-
Taipei, Taiwan
- GSK Investigational Site
-
-
-
-
-
Bangkok, Thailand, 10400
- GSK Investigational Site
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- A male or female child aged 6 to 35 months at the time of the first vaccination; children who may or may not have had previous administration of influenza vaccine in a previous season are acceptable.
- Subjects having a parent/guardian who the investigator believes can and will comply with the requirements of the protocol.
- Written informed consent obtained from the subject's parent/guardian.
Exclusion Criteria:
- Use of any investigational or non-registered product (drug or vaccine) within 30 days preceding the administration of the study vaccine, or planned use during the study period. Routine, registered childhood vaccinations are not an exclusion criterion.
- History of hypersensitivity to any vaccine.
- History of allergy or reactions likely to be exacerbated by any component of the vaccine.
- Acute disease at the time of enrolment.
- History of Guillain Barré syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
- Receipt of an influenza vaccine outside of this study, during current (2008-09) flu season.
- Administration of immunoglobulins and/or blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Fluarix Dose A Group
Subjects were administered 1 or 2 doses* of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Eksperimentell: Fluarix Dose B Group
Subjects were administered 1 or 2 doses*, half the volume of dose A, of Fluarix vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
Two different doses are tested.
|
|
Aktiv komparator: Fluzone Group
Subjects were administered 1 or 2 doses* of Fluzone vaccine (at Day 0 or at Days 0 and 28) intramuscularly, in the non-dominant upper arm (children >12 months of age) or in the anterolateral thigh (children <12 months of age). * Only those subjects who had no history of prior influenza vaccination (i.e. unprimed subjects) received 2 doses. |
One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies Against Each of the Influenza Vaccine Strains
Tidsramme: Day 0 (PRE), Day 28 or Day 56 (POST)
|
GMTs and their 95% confidence interval are presented for all 3 viral strains comprised in the vaccine. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Number of Subjects Who Seroconverted
Tidsramme: Day 28 or Day 56
|
Seroconversion is defined as the number of subjects with either a pre-vaccination anti-HA titer < 1:10 and a post-vaccination titer ≥ 1:40, or a pre-vaccination titer ≥ 1:10 and a minimum 4-fold increase at post-vaccination titer. Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Seroprotected Subjects
Tidsramme: Day 0 (PRE), Day 28 or Day 56 (POST)
|
A seroprotected subject is a subject with a serum anti-HA titer ≥ 1:40 Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 0 (PRE), Day 28 or Day 56 (POST)
|
|
Seroconversion Factor
Tidsramme: Day 28 or Day 56
|
Seroconversion factor is defined as the fold increase in serum anti-HA GMTs post-vaccination (Day 28 or 56) compared to pre-vaccination (Day 0). Post-vaccination timepoints: Day 28 for primed or Day 56 for unprimed subjects |
Day 28 or Day 56
|
|
Number of Subjects Reporting Solicited Local Symptoms
Tidsramme: During a 4-day follow-up period after vaccination
|
Solicited local symptoms assessed include pain, redness and swelling.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Solicited General Symptoms
Tidsramme: During a 4-day follow-up period after vaccination
|
Solicited general symptoms assessed include drowsiness, irritability, loss of appetitie, and temperature.
|
During a 4-day follow-up period after vaccination
|
|
Number of Subjects Reporting Unsolicited Adverse Events (AE)
Tidsramme: During a 28-day follow-up period after vaccination
|
An AE is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product
|
During a 28-day follow-up period after vaccination
|
|
Number of Subjects Reporting Serious Adverse Events (SAE) and New Onset of Chronic Diseases (NOCD)
Tidsramme: During the entire study (Day 0 until Month 6)
|
An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study subject, or may evolve into one of the outcomes listed above. NOCDs assessed include for example: diabetes, asthma, allergies, autoimmune disease, cancer, neuropathic disorders |
During the entire study (Day 0 until Month 6)
|
|
Number of Subjects Reporting Rare Serious Events
Tidsramme: During the entire study (Day 0 until Month 6)
|
Rare serious events have an occurrence rate of 1/300 (0.3%).
|
During the entire study (Day 0 until Month 6)
|
Samarbeidspartnere og etterforskere
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Li-Kim-Moy J, Wood N, Jones C, Macartney K, Booy R. Impact of Fever and Antipyretic Use on Influenza Vaccine Immune Reponses in Children. Pediatr Infect Dis J. 2018 Oct;37(10):971-975. doi: 10.1097/INF.0000000000001949.
- Pavia-Ruz N, Angel Rodriguez Weber M, Lau YL, Nelson EA, Kerdpanich A, Huang LM, Silas P, Qaqundah P, Blatter M, Jeanfreau R, Lei P, Jain V, El Idrissi M, Feng Y, Innis B, Peeters M, Devaster JM. A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 months of age. Hum Vaccin Immunother. 2013 Sep;9(9):1978-88. doi: 10.4161/hv.25363. Epub 2013 Jun 19.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 111751
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Studiedata/dokumenter
-
Datasettspesifikasjon
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Skjema for informert samtykke
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Statistisk analyseplan
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Annotert saksrapportskjema
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Klinisk studierapport
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Datasett for individuell deltaker
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
-
Studieprotokoll
Informasjonsidentifikator: 111751Informasjonskommentarer: For additional information about this study please refer to the GSK Clinical Study Register
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .